Creative Planning Has $111,000 Position in MaxCyte, Inc. (NASDAQ:MXCT)

Creative Planning grew its holdings in MaxCyte, Inc. (NASDAQ:MXCT) by 33.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 28,652 shares of the company’s stock after buying an additional 7,212 shares during the quarter. Creative Planning’s holdings in MaxCyte were worth $111,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Russell Investments Group Ltd. bought a new stake in MaxCyte in the first quarter valued at $28,000. Price T Rowe Associates Inc. MD grew its holdings in shares of MaxCyte by 20.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 25,199 shares of the company’s stock worth $106,000 after purchasing an additional 4,320 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in MaxCyte by 22.1% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 32,735 shares of the company’s stock valued at $128,000 after purchasing an additional 5,927 shares during the last quarter. SG Americas Securities LLC lifted its holdings in MaxCyte by 84.5% during the 3rd quarter. SG Americas Securities LLC now owns 37,969 shares of the company’s stock valued at $148,000 after purchasing an additional 17,385 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in MaxCyte by 25.0% in the second quarter. The Manufacturers Life Insurance Company now owns 42,289 shares of the company’s stock valued at $166,000 after buying an additional 8,454 shares in the last quarter. 68.81% of the stock is owned by institutional investors.

Insider Transactions at MaxCyte

In related news, Director Stanley C. Erck sold 21,607 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $3.71, for a total value of $80,161.97. Following the completion of the transaction, the director now owns 269,118 shares in the company, valued at $998,427.78. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, Director Stanley C. Erck sold 21,607 shares of the business’s stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $3.71, for a total transaction of $80,161.97. Following the completion of the sale, the director now owns 269,118 shares in the company, valued at $998,427.78. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Stanley C. Erck sold 29,767 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $3.97, for a total value of $118,174.99. Following the completion of the transaction, the director now owns 269,118 shares in the company, valued at approximately $1,068,398.46. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 60,374 shares of company stock worth $233,797. Corporate insiders own 3.00% of the company’s stock.

MaxCyte Trading Down 1.1 %

NASDAQ:MXCT opened at $3.54 on Wednesday. The stock has a market capitalization of $373.41 million, a P/E ratio of -10.53 and a beta of 1.40. MaxCyte, Inc. has a 1 year low of $3.23 and a 1 year high of $5.55. The firm has a 50 day moving average of $3.82 and a 200-day moving average of $4.18.

MaxCyte (NASDAQ:MXCT) last announced its earnings results on Wednesday, November 6th. The company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.02. MaxCyte had a negative return on equity of 16.00% and a negative net margin of 78.36%. The company had revenue of $8.16 million for the quarter, compared to analysts’ expectations of $7.50 million. During the same quarter in the prior year, the business earned ($0.11) earnings per share. As a group, analysts forecast that MaxCyte, Inc. will post -0.43 EPS for the current fiscal year.

About MaxCyte

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.